Rivoglitazone

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Rivoglitazone
File:Rivoglitazone.svg
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H19N3O4S
Molar mass397.448 g/mol
3D model (JSmol)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes.[1]

It is being developed by Daiichi Sankyo Co.

References

  1. Schimke K, Davis TM (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs. 8 (4): 338–44. PMID 17458185.

Template:Oral hypoglycemics

Template:WH Template:WS